Valneva SE
6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com
版塊: Healthcare
行業: Biotechnology
全職員工: 676
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Thomas Lingelbach | President, CEO & Director | 1M | 無 | 1963 |
| Mr. Peter Buhler | Chief Financial Officer | 608.52k | 無 | 1971 |
| Mr. Frederic Jacotot | VP of Legal & IP, General Counsel, and Corporate Secretary | 332.34k | 無 | 1964 |
| Mr. Franck Grimaud MBA | Chief Business Officer | 437.02k | 無 | 1967 |
| Dr. Juan-Carlos Jaramillo M.D. | Chief Medical Officer | 587.75k | 無 | 1972 |
| Ms. Dipal Patel | Chief Commercial Officer | 562.7k | 無 | 1975 |
| Mr. Vincent Dequenne | Chief Operating Officer | 無 | 無 | 1967 |
| Mr. Joshua Drumm Ph.D. | Vice President of Investor Relations | 無 | 無 | 無 |
| Ms. Laetitia Bachelot-Fontaine | VP of Global Communications & European Investor Relations | 無 | 無 | 無 |
| Ms. Petra Pesendorfer | Chief People Officer | 無 | 無 | 1986 |
描述
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
公司管治
截至 2024年5月1日 止，Valneva SE 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：6；董事會：7；股東權利：9；現金賠償：10。
